Tenon Medical (TNON) EBITDA Margin (2021 - 2026)

Tenon Medical's EBITDA Margin history runs 6 years deep, the most recent figure standing at 237.85% for Q1 2026.

• On a quarterly basis, EBITDA Margin rose 26862.0% year-over-year to 237.85% in Q1 2026; TTM through Mar 2026 was 269.63%, a 15476.0% increase from a year earlier, with the FY2025 full-year figure at 324.34%, up 9574.0% from the prior year.
• EBITDA Margin slipped to 237.85% in Q1 2026 per TNON's latest filing, from 193.52% in the prior quarter.
• Across five years, EBITDA Margin topped out at 193.52% in Q4 2025 and bottomed at 4041.48% in Q2 2022.
• The 5-year median for EBITDA Margin is 487.62% (2024), against an average of 1016.6%.
• Across the five-year window, EBITDA Margin slumped 166817 bps in 2022 and soared 345979 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 2862.09% in 2022, then surged by 86 bps to 388.74% in 2023, then dropped by 6 bps to 412.08% in 2024, then surged by 53 bps to 193.52% in 2025, then declined by 23 bps to 237.85% in 2026.
• Per Business Quant, the three latest TNON EBITDA Margin figures stand at 237.85% (Q1 2026), 193.52% (Q4 2025), and 289.17% (Q3 2025).